Yahoo Finance

Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief ...
War on the Rocks

Pathos, Where Art Thou? Intelligence Analysis and Ethical Persuasion

While teaching a class on intelligence and analysis last year, I asked my graduate students why the media’s shocking picture of the drowned Syrian boy seemed to have such an incredible effect on ...
Crain's Chicago Business

Pathos raises $365 million in funding round, touts $1.6 billion valuation

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...
Yahoo Finance

Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development

CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of ...
pharmaphorum

AstraZeneca joins Tempus, Pathos in cancer AI project

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology. The ...